Second-generation antipsychotics in major depressive disorder: update and clinical perspective

Current Opinion in Psychiatry, 12/13/2010

The aim of the systematic review was to examine the efficacy and safety of second–generation antipsychotics (SGAs) in nonpsychotic major depressive disorder (MDD). Both SGA monotherapy and adjunctive therapy showed greater efficacy in the treatment of MDD than placebo, but augmentation is more widely utilized in treatment–resistant depression. Clinicians should routinely monitor for cardiometabolic side–effects and extrapyramidal symptoms during SGA therapy.

Print Article Summary Cat 2 CME Report